Direct RNA Binding Assay for High-Throughput Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for identifying compounds that modulate translation termination and nonsense-mediated mRNA decay are inefficient and lack specificity, particularly in high-throughput screening, and do not effectively detect direct binding to target RNA sequences or structural motifs under physiologic conditions.
Innovation Solution
The development of methods involving direct non-competitive binding assays to identify compounds that bind to specific regions of 28S ribosomal RNA and its analogs, using labeled target RNAs and various physical detection methods to identify complexes formed under physiologic conditions, allowing for high-throughput screening and reducing bias from host cell factors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional competitive binding assays are used to identify compounds that modulate translation termination, then host cell factors are involved in the detection process, but this introduces bias and reduces measurement precision and reliability
Solution Approach 1:
The patent extracts and removes host cell factors from the detection system by using in vitro translation systems and directly detecting compound-RNA interactions without requiring cellular components. This eliminates the bias introduced by host cell factors while maintaining assay reliability.
Solution Approach 2:
The patent introduces labeled target RNAs as intermediaries to detect compound binding. Instead of using complex host cell factors, simple labeled RNA molecules serve as mediators that directly interact with compounds of interest, improving measurement precision while simplifying the overall system.
2Productivity
If high-throughput screening is implemented to identify compounds modulating translation termination, then screening efficiency increases, but current methods lack specificity and direct binding detection capability
Solution Approach 1:
The patent replaces complex cellular-based detection mechanisms with direct physical detection methods. By using labeled RNAs and physical detection techniques, the system achieves both high throughput and high specificity for detecting direct compound-RNA binding interactions.
Solution Approach 2:
The patent changes the detection parameters by using labeled target RNAs and physical detection methods instead of cellular-based assays. This parameter change enables simultaneous achievement of high throughput screening capability and high binding detection specificity.
3Ease of manufacture
If conventional assays are used that do not operate under physiologic conditions, then screening can be performed, but the results lack reliability for predicting in vivo activity
Solution Approach 1:
The patent changes the assay conditions to operate under physiologic parameters including appropriate temperature, pH, and ionic strength. This maintains assay simplicity while significantly improving the reliability and physiologic relevance of the screening results.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These methods enable the efficient identification of compounds that bind to target RNAs, facilitating the modulation of translation termination and nonsense-mediated mRNA decay, thereby providing potential therapeutic agents for diseases caused by premature stop codons.
Implementation Method 1
contacting a target RNA having a detectable label with a library of compounds in solution, and detecting the formation of a target RNA:compound complex
Implementation Method 2
a target RNA having a detectable label with a library of compounds in solution, and detecting the formation of a target RNA:compound complex
Data Source
AI summary
The present invention relates to a method for screening and identifying compounds that modulate premature translation termination and/or nonsense-mediated messenger ribonucleic acid (“mRNA”) by interacting with a preselected target ribonucleic acid (“RNA”). In particular, the present invention relates to identifying compounds that bind to regions of the 28S ribosomal RNA (“rRNA”) and analogs thereof. Direct, noncompetitive binding assays are advantageously used to screen libraries of compounds for those that selectively bind to a preselected target RNA. Binding of target RNA molecules to a particular compound is detected using any physical method that measures the altered physical property of the target RNA bound to a compound. The structure of the compound attached to the labeled RNA is also determined. The methods used will depend, in part, on the nature of the library screened. The methods of the present invention provide a simple, sensitive assay for high-throughput screening of libraries of compounds to identify pharmaceutical leads.